NEWARK, Calif., Jan. 9, 2012 (GLOBE NEWSWIRE) -- StemCells, Inc. (Nasdaq:STEM), a leading stem cell company developing and commercializing novel cell-based therapeutics and tools for use in stem cell-based research and drug discovery, announced today that Martin McGlynn, President and CEO, will present a business update at the Biotech Showcase 2012 to be held January 9-11 at the Parc 55 Wyndham Hotel in San Francisco, California. Mr. McGlynn is scheduled to speak on Tuesday, January 10, at 1:45 pm PST.
The Biotech Showcase is a forum devoted to providing life sciences, biotechnology and pharmaceutical companies and investors with an opportunity to meet to discuss investment opportunities and collaborations. The Biotech Showcase is scheduled during the course of one of the world's largest annual healthcare conferences which annually attracts thousands of healthcare and life science business executives and investors to San Francisco. Investors are invited to attend on a complimentary basis. More information is available at www.ebdgroup.com/bts" target="_top" rel="nofollow">www.ebdgroup.com/bts.
About StemCells, Inc.
StemCells, Inc. is engaged in the research, development, and commercialization of cell-based therapeutics and tools for use in stem cell-based research and drug discovery. The Company's lead therapeutic product candidate, HuCNS-SC® cells (purified human neural stem cells), is currently in development as a potential treatment for a broad range of central nervous system disorders. Clinical trials are currently underway in spinal cord injury and in Pelizaeus-Merzbacher disease (PMD), a fatal myelination disorder in children. In addition, the Company plans to initiate a clinical trial of HuCNS-SC cells in the dry form of age-related macular degeneration in 2012, and is also pursuing preclinical studies of its HuCNS-SC cells in Alzheimer's disease. StemCells also markets stem cell research products, including media and reagents, under the SC Proven® brand, and is developing stem cell-based assay platforms for use in pharmaceutical research, drug discovery and drug development. Further information about StemCells is available at http://www.stemcellsinc.com.
The StemCells, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7014
Apart from statements of historical fact, the text of this press release constitutes forward-looking statements within the meaning of the U.S. securities laws, and is subject to the safe harbors created therein. These statements include, but are not limited to, statements regarding the clinical development of its HuCNS-SC cells; the timing and prospects associated with initiating a clinical trial in age-related macular degeneration; the Company's ability to commercialize drug discovery and drug development tools; and the future business operations of the Company. These forward-looking statements speak only as of the date of this news release. The Company does not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. Such statements reflect management's current views and are based on certain assumptions that may or may not ultimately prove valid. The Company's actual results may vary materially from those contemplated in such forward-looking statements due to risks and uncertainties to which the Company is subject, including those described under the heading "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2010 and in its subsequent reports on Forms 10-Q and 8-K.